SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-054279
Filing Date
2024-06-20
Accepted
2024-06-20 16:05:31
Documents
13
Period of Report
2024-06-20
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0208180-8k_unicycive.htm   iXBRL 8-K 47934
  Complete submission text file 0001213900-24-054279.txt   224371

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE uncy-20240620.xsd EX-101.SCH 3018
3 XBRL LABEL FILE uncy-20240620_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE uncy-20240620_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0208180-8k_unicycive_htm.xml XML 3779
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 241056204
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)